bizelesin

structure given in first source

Also Known As:

Benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*))); U 77779; U-77,779; U-77779; U-78779; U78779

Networked: 12 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Duocarmycins: 63
        bizelesin: 12
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Duocarmycins: 63
        bizelesin: 12
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - bizelesin: 12

Experts

1.	Bai, Shaochun: 1 article (05/2004)
2.	Goodrich, David W: 1 article (05/2004)
3.	Herman, Terence S: 1 article (11/2003)
4.	Herzig, Maryanne C: 1 article (11/2003)
5.	Jackson, Jennifer A: 1 article (11/2003)
6.	Trevino, Alex V: 1 article (11/2003)
7.	Woynarowski, Jan M: 1 article (11/2003)
8.	Beerman, Terry: 1 article (07/2003)
9.	Cao, Pei-rang: 1 article (07/2003)
10.	McHugh, Mary M: 1 article (07/2003)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2002 - "A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors." 05/01/2003 - "Patients with advanced solid malignancies were treated with escalating doses of bizelesin as an i.v. bolus injection every 4 weeks. " 03/01/2002 - "Patients with advanced solid tumors received escalating doses of bizelesin as an i.v. push every 4 weeks. " 07/01/1996 - "Bizelesin was evaluated for antitumor activity against a broad spectrum of syngeneic murine tumors and human tumor xenografts in mice. " 11/01/2003 - "AT-rich minisatellites (AT islands) are sites of genomic instability in cancer cells and targets for extremely lethal AT-specific drugs, such as bizelesin. "
2.	Carcinoma (Carcinomatosis) 05/17/1994 - "Human colon carcinoma cells were treated with adozelesin and bizelesin, and the position of adducts were mapped within the PGK-1 and p53 genes by means of ligation-mediated polymerase chain reaction. " 07/01/2003 - "The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells." 12/15/1991 - "DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779." 05/01/2004 - "To address this question, HCT116 colon carcinoma cells have been treated with equally cytotoxic doses of the antitumor DNA alkylating agents adozelesin or bizelesin or the DNA strand scission agent C-1027. "
3.	Genomic Instability 11/01/2003 - "AT-rich minisatellites (AT islands) are sites of genomic instability in cancer cells and targets for extremely lethal AT-specific drugs, such as bizelesin. "
4.	Hematologic Neoplasms (Hematological Malignancy) 05/01/2003 - "The characteristics of the myelosuppression, the paucity of severe toxicities with repetitive treatment, the preliminary antitumor activity noted, and, above all, its unique mechanism of action as a selective DNA-damaging agent and high potency, warrant disease-directed evaluations of bizelesin in solid and hematopoietic malignancies and consideration of its use as a cytotoxic in targeted conjugated therapeutics."
5.	Neutropenia 03/01/2002 - "Bizelesin administered every 4 weeks as an i.v. push is well tolerated with dose-limiting toxicity of neutropenia. "

Related Drugs and Biologics

1.	Antineoplastic Agents (Antineoplastics)
2.	DNA (Deoxyribonucleic Acid)
3.	adozelesin
4.	Doxorubicin (Adriamycin)
5.	Vinblastine (Vinblastine Sulfate)
6.	Melphalan (Alkeran)
7.	Cytotoxins (Cytolysins)
8.	Cisplatin (Platino)
9.	Alkylating Agents
10.	carzelesin

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation